Evidence map›Paper›PMID 27044079›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Pathogen receptor discovery with a microfluidic human membrane protein array.

Yair Glick, Ya'ara Ben-Ari, Nir Drayman, Michal Pellach, Gregory Neveu, Jim Boonyaratanakornkit, Dorit Avrahami, Shirit Einav, Ariella Oppenheim, Doron Gerber

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Viral journeys on the intracellular highways.Cellular and molecular life sciences : CMLS · 2018
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yair GlickMina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, 5290002, Israel;
Ya'ara Ben-AriMina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, 5290002, Israel;
Nir DraymanFaculty of Medicine, Hebrew University, Jerusalem, 9112001, Israel;
Michal PellachMina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, 5290002, Israel;
Gregory NeveuDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305.
Jim BoonyaratanakornkitDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305.
Dorit AvrahamiMina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, 5290002, Israel;
Shirit EinavDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305.
Ariella OppenheimFaculty of Medicine, Hebrew University, Jerusalem, 9112001, Israel;
Doron GerberMina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, 5290002, Israel; doron.gerber@biu.ac.il.ORCID http://orcid.org/0000-0002-0532-2928

Funding

Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1UL1TR000093 · NCATS · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2012 to 2013
$6.5M
Doris Duke Charitable Foundation 2013100NCATS NIH HHS UL1 TR000093NCATS NIH HHS UL1 TR001085
6 · The paper itself

Abstract

The discovery of how a pathogen invades a cell requires one to determine which host cell receptors are exploited. This determination is a challenging problem because the receptor is invariably a membrane protein, which represents an Achilles heel in proteomics. We have developed a universal platform for high-throughput expression and interaction studies of membrane proteins by creating a microfluidic-based comprehensive human membrane protein array (MPA). The MPA is, to our knowledge, the first of its kind and offers a powerful alternative to conventional proteomics by enabling the simultaneous study of 2,100 membrane proteins. We characterized direct interactions of a whole nonenveloped virus (simian virus 40), as well as those of the hepatitis delta enveloped virus large form antigen, with candidate host receptors expressed on the MPA. Selected newly discovered membrane protein-pathogen interactions were validated by conventional methods, demonstrating that the MPA is an important tool for cellular receptor discovery and for understanding pathogen tropism.

Indexed as

HumansMicrofluidic Analytical TechniquesProtein Array AnalysisProteomicsReceptors, VirusSimian virus 40Receptors, Virusintegrated microfluidicsmembrane protein arraypathogen–host interactionsreceptor discovery

Identifiers

PMID27044079
PMCPMC4843447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.